Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28 : pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*
Summary Background The phase III reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti‐interleukin‐23p19 monoclonal antibody tildrakizumab (TIL) for psoriasis treatment are complete. Objectives We present 5‐year pooled data from reSURFACE 1 and reSURFACE 2. Methods reSURFACE 1 and reSURFACE 2 were double‐blind, randomized, controlled studies with optional long‐term extensions. Adults with moderate‐to‐severe chronic plaque psoriasis were randomized 2 : 2 : 1 to TIL 100 mg (TIL 100) or 200 mg (TIL 200) or placebo at weeks 0 and 4, and every 12 weeks thereafter [reSURFACE 2 included an etanercept (ETN) arm]. Efficacy outcomes included proportions of patients achieving absolute and relative improvement from baseline Psoriasis Area and Severity Index (PASI) score through week 244 in TIL responders (≥ 75% improvement from baseline PASI; PASI 75 response) continuously receiving the same dose and ETN partial responders and nonresponders (PASI < 75 response) switched to TIL 200 at week 28. Safety was assessed from adverse events (AEs) in all patients as treated. Results Efficacy analyses included 329 and 227 week 28 responders to TIL 100 and TIL 200, respectively, and 121 ETN partial responders/nonresponders switched to TIL 200 at week 28. Of TIL 100 or TIL 200 responders and ETN partial responders/nonresponders entering the extensions, 235/302, 176/213 and 85/107, respectively, were evaluated at week 244, and 88·7%, 92·5% and 81·3%, respectively, achieved PASI 75 response. Exposure‐adjusted rates of serious AEs were 6·3 and 6·0 patients with events per 100 patient‐years of TIL 100 and TIL 200, respectively. Conclusions TIL treatment provided sustained disease control over 5 years in week 28 TIL responders and ETN partial responders/nonresponders, with a reassuring safety profile..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
|---|---|
| Enthalten in: |
British Journal of Dermatology - 185(2021), 2, Seite 323-334 |
| Beteiligte Personen: |
Thaci, D. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2021 British Association of Dermatologists |
|---|
| Umfang: |
12 |
|---|
| doi: |
10.1111/bjd.19866 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002773635 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002773635 | ||
| 003 | DE-627 | ||
| 005 | 20230307121847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bjd.19866 |2 doi | |
| 028 | 5 | 2 | |a BJD_BJD19866.xml |
| 035 | |a (DE-627)WLY002773635 | ||
| 035 | |a (WILEY)BJD19866 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.93 |2 bkl | ||
| 100 | 1 | |a Thaci, D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28 |b pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)* |
| 264 | 1 | |c 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2021 British Association of Dermatologists | ||
| 520 | |a Summary Background The phase III reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti‐interleukin‐23p19 monoclonal antibody tildrakizumab (TIL) for psoriasis treatment are complete. Objectives We present 5‐year pooled data from reSURFACE 1 and reSURFACE 2. Methods reSURFACE 1 and reSURFACE 2 were double‐blind, randomized, controlled studies with optional long‐term extensions. Adults with moderate‐to‐severe chronic plaque psoriasis were randomized 2 : 2 : 1 to TIL 100 mg (TIL 100) or 200 mg (TIL 200) or placebo at weeks 0 and 4, and every 12 weeks thereafter [reSURFACE 2 included an etanercept (ETN) arm]. Efficacy outcomes included proportions of patients achieving absolute and relative improvement from baseline Psoriasis Area and Severity Index (PASI) score through week 244 in TIL responders (≥ 75% improvement from baseline PASI; PASI 75 response) continuously receiving the same dose and ETN partial responders and nonresponders (PASI < 75 response) switched to TIL 200 at week 28. Safety was assessed from adverse events (AEs) in all patients as treated. Results Efficacy analyses included 329 and 227 week 28 responders to TIL 100 and TIL 200, respectively, and 121 ETN partial responders/nonresponders switched to TIL 200 at week 28. Of TIL 100 or TIL 200 responders and ETN partial responders/nonresponders entering the extensions, 235/302, 176/213 and 85/107, respectively, were evaluated at week 244, and 88·7%, 92·5% and 81·3%, respectively, achieved PASI 75 response. Exposure‐adjusted rates of serious AEs were 6·3 and 6·0 patients with events per 100 patient‐years of TIL 100 and TIL 200, respectively. Conclusions TIL treatment provided sustained disease control over 5 years in week 28 TIL responders and ETN partial responders/nonresponders, with a reassuring safety profile. | ||
| 700 | 1 | |a Piaserico, S. |4 aut | |
| 700 | 1 | |a Warren, R.B. |4 aut | |
| 700 | 1 | |a Gupta, A.K. |4 aut | |
| 700 | 1 | |a Cantrell, W. |4 aut | |
| 700 | 1 | |a Draelos, Z. |4 aut | |
| 700 | 1 | |a Foley, P. |4 aut | |
| 700 | 1 | |a Igarashi, A. |4 aut | |
| 700 | 1 | |a Langley, R.G. |4 aut | |
| 700 | 1 | |a Asahina, A. |4 aut | |
| 700 | 1 | |a Young, M. |4 aut | |
| 700 | 1 | |a Falqués, M. |4 aut | |
| 700 | 1 | |a Pau‐Charles, I. |4 aut | |
| 700 | 1 | |a Mendelsohn, A.M. |4 aut | |
| 700 | 1 | |a Rozzo, S.J. |4 aut | |
| 700 | 1 | |a Reich, K. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Dermatology |g 185(2021), 2, Seite 323-334 |w (DE-627)WLY002735717 |x 13652133 |7 nnns |
| 773 | 1 | 8 | |g volume:185 |g year:2021 |g number:2 |g pages:323-334 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.93 |q ASE |
| 951 | |a AR | ||
| 952 | |d 185 |j 2021 |e 2 |h 323-334 |g 12 | ||